A phase II open-label, non-comparative, international, multicentre study to assess the efficacy and safety of KU 0059436 [KU 59436] given orally twice daily in patients with advanced BRCA1 or BRCA2 associated ovarian cancer
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Olaparib (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms ICEBERG-2
- Sponsors AstraZeneca; KuDOS Pharmaceuticals
- 14 Sep 2017 Status changed from active, no longer recruiting to completed.
- 27 Dec 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 08 Mar 2016 Results (pooled analysis of this and five other studies (n = 300) assessing olaparib monotherapy in patients with advanced relapsed BRCA1/2 ovarian cancer) published in the Annals of Oncology.